|Home | About | Journals | Submit | Contact Us | Français|
The serotonin-1A (5-HT1A) receptor is an abundant post-synaptic 5-HT receptor (heteroreceptor) implicated in regulation of mood, emotion and stress responses and is the major somatodendritic autoreceptor that negatively regulates 5-HT neuronal activity. Based on animal models, an integrated model for opposing roles of pre- and post-synaptic 5-HT1A receptors in anxiety and depression phenotypes and response to antidepressants is proposed. Understanding differential transcriptional regulation of pre- versus post-synaptic 5-HT1A receptors could provide better tools for their selective regulation. This review examines the transcription factors that regulate brain region-specific basal and stress-induced expression of the 5-HT1A receptor gene (Htr1a). A functional polymorphism, rs6295 in the Htr1a promoter region, blocks the function of specific repressors Hes1, Hes5 and Deaf1, resulting in increased 5-HT1A autoreceptor expression in animal models and humans. Its association with altered 5-HT1A expression, depression, anxiety and antidepressant response are related to genotype frequency in different populations, sample homogeneity, disease outcome measures and severity. Preliminary evidence from gene × environment studies suggests the potential for synergistic interaction of stress-mediated repression of 5-HT1A heteroreceptors, and rs6295-induced upregulation of 5-HT1A autoreceptors. Targeted therapeutics to inhibit 5-HT1A autoreceptor expression and induce 5-HT1A heteroreceptor expression may ameliorate treatment of anxiety and major depression.
The 5-HT1A receptor has been increasingly associated with alterations in mood and emotion and has opposing functions as a pre-synaptic somatodendritic autoreceptor and a post-synaptic heteroreceptor. The 5-HT1A autoreceptor mediates negative feedback inhibition on 5-HT neurons, while the 5-HT1A heteroreceptors mediate 5-HT actions on target neurons. We focus on the transcriptional mechanisms and polymorphic changes that regulate pre- versus post-synaptic 5-HT1A receptors, and how this differential regulation could be used to understand the etiology and improve the treatment of mental illnesses.
The concept of the ‘autoreceptor’ as a receptor that regulates (usually inhibits) the release of its own neurotransmitter goes back to the 1960s, originally described by Carlsson and colleagues [1,2] for the dopamine system. The key observations that these receptors regulate release of their own neurotransmitters came from evidence that by inhibiting autoreceptors using pharmacological blockers such as haloperidol or chlorpromazine, dopamine release and turnover was greatly augmented. Oppositely, agonists such as apomorphine suppressed basal dopamine release. These key observations were replicated in the noradrenergic and serotonergic systems, and now the concept of autoreceptors has been generalized to include a number of other systems, including histaminergic, glutaminergic, cholinergic and other major neurotransmitter systems .
For the serotonin (5-hydroxytryptamine, 5-HT) system, the presence of autoreceptors was indicated by evidence that non-selective agonist LSD or 5-HT itself reduced 5-HT release, while receptor antagonists like methiothepin increased 5-HT release . Aghajanian's group showed that autoregulation of firing was mediated by 5-HT receptors on the 5-HT neurons [5–7]. Using the selective agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), Hamon's group identified the 5-HT1A receptor as the major autoreceptor on the cell body and dendrites of 5-HT neurons of the raphe nuclei [8–11]. The 5-HT1A autoreceptor was then shown to mediate 5-HT auto-inhibition [7,12]. A consistent observation has been that reduction or ablation of 5-HT1A autoreceptors leads to increased 5-HT neurotransmission [13–17], while over-expression of 5-HT1A autoreceptors reduces 5-HT neurotransmission [18–20]. While 5-HT1A antagonists do not greatly affect basal firing, they consistently reverse inhibition of firing by 5-HT1A agonist or specific reuptake inhibitor (SSRI) treatment, suggesting that the basal level of 5-HT under recording conditions may be insufficient to see effects. In 5-HT1A knockout animals, an elevated basal raphe firing may result from a chronic absence of 5-HT1A receptors. By contrast, the 5-HT1B subtype is the key autoreceptor on presynaptic 5-HT nerve terminals regulating 5-HT release [21,22]. Recently, targeting of the 5-HT1A autoreceptor to soma and dendrites has been shown to be mediated by interaction of the receptor C-terminal tail with Yif1B [23,24]. 5-HT1A-mediated autoinhibition involves 5-HT1A-induced hyperpolarization of raphe neurons that is mediated by coupling of pertussis toxin-sensitive Gi proteins to activation of inward-rectifying potassium (GIRK) channels [25–28], possibly GIRK2 channels , which are co-expressed with 5-HT1A receptors in raphe and post-synaptic regions . In addition, 5-HT1A heteroreceptors mediate an indirect negative feedback pathway by inhibition of pyramidal cortical neurons that project to raphe 5-HT neurons . Oppositely, 5-HT2A and 5-HT4 receptors mediate positive feedback of 5-HT neurons via prefrontal cortex and hippocampus projections, respectively [31,32]. Together, the direct and indirect 5-HT1A-mediated feedback mechanisms negatively regulate the activity of the 5-HT system.
Release of 5-HT1A-mediated autoinhibition by receptor desensitization appears to play a key role in the efficacy of antidepressant treatments, especially 5-HT-SSRIs [13,33–35]. Acute treatment with SSRI leads to a local increase in 5-HT levels in the raphe nuclei [36,37], activating 5-HT1A-mediated autoinhibition to inhibit firing of 5-HT neurons. With chronic SSRI treatment, 5-HT1A autoreceptors (but not heteroreceptors) desensitize, restoring raphe firing to enhance 5-HT release. By contrast, sensitization of 5-HT1A heteroreceptors is observed following chronic antidepressant treatment, although the mechanisms involved remain unclear [38–43].
Activation of 5-HT1A heteroreceptors plays a prominent role in the antidepressant and neurogenic actions of SSRIs [44–46]. Several possible mechanisms have been implicated in 5-HT1A autoreceptor desensitization  including uncoupling from G-proteins [41,47–50], receptor internalization , G-protein inactivation  and reduction in 5-HT1A autoreceptors [38,53]. In addition, coupling to the GIRK is reduced upon chronic fluoxetine treatment , one mechanism that may disinhibit raphe firing and allow for enhanced 5-HT neurotransmission. However, these mechanisms of rapid desensitization do not account for the chronic treatment required for antidepressant effects, and are also rapidly reversible . The above studies were done in normal animals, while in animal models of depression chronic antidepressant treatment leads to a downregulation of 5-HT1A autoreceptor RNA or binding sites in the raphe nuclei [55–57] (figure 1). Similarly, in human depression in elderly subjects a reduction in 5-HT1A autoreceptors was correlated with an increased response to SSRI treatment , while another study found that in patients treated with SSRIs, increased 5-HT1A autoreceptor availability correlated with more severe depression . Thus, while rapid desensitization of 5-HT1A autoreceptors occurs, transcriptional downregulation of 5-HT1A autoreceptors may play a role in the long-term adaptive changes in response to chronic antidepressant treatment in depressed subjects. Consistent with this, mice engineered to repress 5-HT1A autoreceptor expression in adults by only 30 per cent responded to chronic SSRI treatment within days, while wild-type mice failed to respond to a three-week treatment . Since partial or complete repression of 5-HT1A autoreceptors enhances 5-HT neuronal activity and 5-HT release in target tissues [19,20,60], these studies clearly indicate the level of 5-HT1A autoreceptors serves as a gate for response to chronic SSRI treatment .
Alterations in 5-HT1A receptor expression result in anxiety- and depression-like behaviours in animal models. Knockout of the 5-HT1A receptor gene leads to increased anxiety behaviour in at least three different mouse strains [62–64]. Specific repression of 5-HT1A autoreceptors also increases anxiety, suggesting that their loss leads to increased activation of other post-synaptic 5-HT receptors . Pharmacological blockade of 5-HT1A receptors in early post-natal development also elicits an anxiety phenotype , while early post-natal expression of forebrain 5-HT1A receptors rescues the anxiety phenotype of 5-HT1A-null mice . Similarly, transient over-expression of 5-HT1A receptors reduces anxiety in mice . Selective repression of 5-HT1A heteroreceptors leads to depression-like behaviour, consistent with a role for post-synaptic 5-HT1A receptors in depression . In agreement with this, enhancement of 5-HT1A-Gi2 signalling reduced depression-like behaviours, presumably via 5-HT1A heteroreceptor signalling . Furthermore, 5-HT1A heteroreceptors appear to be obligatory for response to chronic SSRI treatment since 5-HT1A knockout mice lack behavioural and neurogenic response to SSRI . Thus, 5-HT1A heteroreceptors appear critical for both the development of the depression phenotype as well as the antidepressant response to chronic SSRI treatment. Conversely, the 5-HT1A autoreceptor negatively regulates the activity of 5-HT neurons, and restrains the development of the anxiety phenotype as well as reducing and delaying response to SSRI treatment in mouse models (figure 1).
The earlier-mentioned results indicate the importance of the 5-HT1A autoreceptor as a brake for 5-HT neurotransmission in vivo, suggesting that regulators of the Htr1a gene might affect basal 5-HT neurotransmission and susceptibility to depression or anxiety disorders (figure 1). The Htr1a gene lacks introns in its coding region and is strongly expressed in specific brain regions, but almost not at all in non-neuronal tissues [69,70]. The Htr1a gene contains a GC-rich proximal promoter region containing DNA elements for several ubiquitous transcription factors, including Myc-associated zinc finger protein (MAZ), Sp1 and NFκB that drive its expression in all cell types examined [71–73]. By contrast, the Htr1a promoter also contains several Pet-1 sites recognized by the raphe-specific enhancer, Pet-1, which primarily enhances 5-HT1A autoreceptor expression . Knockout of Pet-1 leads to reduced expression of 5-HT1A autoreceptors, as well as a general reduction in serotonergic differentiation markers [74,75]. Thus, Pet-1 is a key positive regulator of 5-HT1A autoreceptor expression.
To restrict Htr1a expression to neuronal cells, a series of repressor elements located upstream of the promoter coordinately silence the gene . These include the RE-1 site for neural restrictive factor (REST/NRSF)  and a powerful dual repressor element that is regulated by a pair of conserved repressors, Freud-1/CC2D1A and Freud-2/CC2D1B [77–79]. Unlike REST, which silences neuronal genes mainly in non-neuronal cells, Freud-1 and Freud-2 also repress 5-HT1A expression in neuronal cells . Reduction of Freud-1 or Freud-2 expression using antisense or siRNA increases expression of neuronal 5-HT1A receptors [78–81]. Together, these repressors silence the Htr1a gene in non-neuronal cells, but reversibly regulate its expression in 5-HT1A-positive neuronal cells. In raphe cells, Freud-1 is co-expressed with 5-HT1A autoreceptors and represses the Htr1a gene, while in target regions both Freud-1 and Freud-2 are expressed, and they both repress Htr1a expression in non-serotonergic neuronal cells. Thus, Freud-1 is implicated in 5-HT1A autoreceptor expression, while both Freud-1 and Freud-2 regulate 5-HT1A heteroreceptor expression.
Another region implicated in 5-HT1A autoreceptor regulation is the C(-1019)G (rs6295) Htr1a promoter polymorphism located within a palindrome (inverted repeat) sequence that is recognized by transcription factors NUDR/Deaf1 and Hes proteins Hes1 and Hes5 [82,83]. In raphe cells, Deaf1 and Hes repress Htr1a and the polymorphic change prevents their binding and repression, upregulating 5-HT1A autoreceptor expression. Hes1 and Hes5 are restricted to neuronal progenitors and silenced upon neuronal differentiation . Knockout of Hes1 results in premature and expanded expression of midbrain 5-HT1A receptor RNA, suggesting a role for Hes1 to restrict 5-HT1A receptor expression to serotonergic neurons . Recent results indicate that knockout of Deaf1 results in a 50 per cent increase in 5-HT1A autoreceptor expression in dorsal and medial raphe nuclei . Thus, by disrupting repression both by Hes1/5 and by Deaf1, the G(-1019) allele is expected to increase 5-HT1A autoreceptor expression, reducing serotonergic activity and increasing the risk of depression (figure 1).
It is important to note that all of these transcriptional mechanisms interact to regulate 5-HT1A autoreceptor expression. For example, reduction in calcium levels by 5-HT1A autoreceptor signalling could relieve calcium-dependent inactivation of Freud-1 , leading to agonist-induced downregulation of Htr1a transcription. Oppositely, along with a trend for an increase in 5-HT1A RNA in raphe tissue from depressed versus control female subjects, REST and Deaf-1 RNA were also increased, suggesting a compensatory mechanism to normalize 5-HT1A autoreceptor expression . Thus, transcriptional upregulation of the 5-HT1A autoreceptor in depression could be blunted by altered regulation of these key repressors in raphe cells.
Differential transcriptional regulation of 5-HT1A autoreceptors versus heteroreceptors is partly dictated by developmental and regional distribution of Htr1a transcriptional factors and alterations in regulators such as glucocorticoids. Thus, Pet-1 is raphe-specific, while Freud-2 is not detected in raphe cells and thus specifically regulates 5-HT1A heteroreceptors. Similarly, high- and low-affinity glucocorticoid receptors (mineralocorticoid receptor, MR, and glucocorticoid receptor, GR, respectively) are enriched in hippocampus compared with raphe and are critical for stress- or glucocorticoid-induced downregulation of hippocampal 5-HT1A receptors [40,71,87–92]. Consistent with the importance of negative regulation of 5-HT1A heteroreceptors by glucocorticoids, an inverse correlation between glucocorticoid levels and hippocampal and amygdala but not raphe 5-HT1A receptor levels is seen in anxiety disorder patients . With elevated glucocorticoid conditions, such as in chronic mild stress or sleep deprivation [94,95], GR appears to repress 5-HT1A autoreceptors . Glucocorticoids can also uncouple 5-HT1A autoreceptors by reducing GIRK2 RNA levels . Paradoxically, over-expression of MR or GR in the mouse forebrain increases 5-HT1A heteroreceptor expression (possibly via suppression of glucocorticoids), which was associated with an anti-anxiety/anti-depressed phenotype and increased SSRI responsiveness, respectively [97,98]. Thus, chronic life stress may dysregulate the 5-HT system by reducing 5-HT1A heteroreceptor expression and increase susceptibility to mental illness (figure 1).
Several lines of evidence suggest that depression and anxiety disorders in humans are associated with alterations in 5-HT1A receptor expression. An increase in 5-HT1A autoreceptor expression has been reported in the rostral raphe region of post-mortem tissue from a depressed suicide victim compared with control subjects, but with reduced 5-HT1A autoreceptor levels in caudal raphe regions [99,100]. Positron emission tomography (PET) imaging studies in living depression patients using the 5-HT1A antagonist [11C]WAY100635 also show a prominent 50 per cent increase in 5-HT1A autoreceptors in antidepressant-free or naive depressed subjects [101–103], as well as a twofold increase in male bipolar depression patients . An upregulation of 5-HT1A autoreceptors is likely to reduce serotonergic neurotransmission, as associated with human depression and suicide (figure 1).
With regard to 5-HT1A heteroreceptor expression, post-mortem studies have generally shown reduced 5-HT1A receptor expression in several regions of the frontal cortex of depressed suicide victims [105,106]. However, in depressed suicide tissue some cortical regions display any increase in 5-HT1A RNA, such as in the frontopolar cortex compared with a decrease in orbital frontal cortex suggesting that dysregulation of 5-HT1A heteroreceptors is region-specific [107,108]. Such region-specific changes in 5-HT1A receptor expression have not been observed in PET imaging studies, but rather global decreases or increases have been observed, which may reflect the limited special resolution of imaging studies . In depression, decreases in 5-HT1A heteroreceptors are more pronounced than for autoreceptors [110–113], which do not change or increase. In panic disorder, there is a reduction in cortical 5-HT1A heteroreceptors that is normalized by treatment [114,115]. Similarly, in social anxiety disorder, reductions in 5-HT1A binding in amygdala and anterior cingulate cortex were most prominent, with some decrease in raphe . Reduced cortical 5-HT1A receptors were correlated with anxiety behaviour in normal subjects [117,118]. These results are consistent with animal studies that indicate a key role for 5-HT1A heteroreceptors in anxiety-like behaviours in mice .
Discrepancies in PET imaging results from different groups may be accounted for by methodological differences in reference tissue [101,119], or by confounds such as limited resolution (e.g. for raphe sub-regions), medication status or ligand competition with receptor-bound 5-HT in vivo. With regard to ligand competition, since PET ligand [11C]WAY100635 is a high-affinity 5-HT1A antagonist, it detects total 5-HT1A receptors, not distinguishing between coupled or uncoupled receptors and is not readily displaced by 5-HT. Treatment of rats with fenfluramine to release synaptic 5-HT reduced [11C]WAY100635 only in hippocampus  but reduced [18F]MPPF (a lower-affinity antagonist) binding in several brain areas . The recent development of a labelled 5-HT1A agonist may provide a sensitive measure of increase in functional 5-HT1A autoreceptors in depression .
Taken together, results from human and animal studies are consistent with a model in which anxiety disorder involves a reduction in 5-HT1A heteroreceptors in limbic areas, such as hippocampus, amygdala and prefrontal cortex, with a lesser decrease in 5-HT1A autoreceptors (figure 1). A reduction or inactivation of 5-HT1A autoreceptors is correlated with increased amygdala activation typical of anxiety phenotypes and is thought to be due to increased 5-HT release . On the other hand, depression appears to be driven by reduced 5-HT neurotransmission, in part due to an increase in pre-synaptic 5-HT1A autoreceptors which inhibits the release of 5-HT. As well, depression is associated with reduced levels of 5-HT1A heteroreceptors, particularly in the hippocampus and prefrontal cortex, that may be induced in part by chronic stress . These results suggest that strategies that target preferentially post-synaptic 5-HT1A heteroreceptors may have greater effects in anxiety , while strategies that both augment 5-HT release and enhance post-synaptic 5-HT1A signalling would be more effective to treat depression. Consistent with this idea, chronic SSRI treatment of anxiety subjects selectively reduced post-synaptic 5-HT1A receptor levels in hippocampus and prefrontal cortex . To date, 5-HT1A ligands, such as buspirone, have lacked selectivity, targeting both pre- and post-synaptic 5-HT1A receptors [127,128], and display limited efficacy for treatment of anxiety or depression. Because autoreceptors and heteroreceptors have opposing actions on serotonergic neurotransmission, these compounds are of limited benefit. Yet, in combination with SSRI, buspirone augments the antidepressant response due to preferential desensitization of 5-HT1A autoreceptors [129,130]. Recently, compounds with selectivity for post-synaptic receptors have been developed  that may demonstrate increased benefit for treatment of anxiety or depression.
It is important to emphasize that multiple mechanisms in addition to 5-HT1A autoreceptor levels regulate 5-HT neurotransmission and could contribute to depression and anxiety. For example, a reduction in TPH2 gene expression or activity , or reduced differentiation of 5-HT neurons as seen in Pet-1-deficient mice reduces 5-HT levels [74,75]. Hence, changes in 5-HT1A autoreceptor levels may be secondary to or enhanced by alterations in 5-HT levels. Furthermore, regional diversity of the raphe nuclei has been suggested, with a Pet-1-insensitive population of 5-HT neurons regulating anxiety behaviour : differential regulation of 5-HT1A receptors within these populations may predispose to anxiety versus depression. Thus, certain populations of 5-HT neurons may display similar levels of 5-HT1A autoreceptors, while others may be affected by the rs6295 polymorphism, stress or other factors. The diversity of mechanisms regulating 5-HT neurotransmission is likely to underlie in part the heterogeneity of results in 5-HT1A receptor levels in depression. Nevertheless, therapeutic strategies that target 5-HT1A autoreceptors could be of benefit by resetting the level of 5-HT neurotransmission (figure 1).
As described earlier, the G(-1019) allele of rs6295 would be expected to cause an upregulation of 5-HT1A autoreceptor expression by preventing Hes1 or Deaf1 repression, but may induce selective reductions in post-synaptic 5-HT1A receptors in specific brain regions due to blocking Deaf1 enhancer activity . Recent PET imaging studies in human-depressed patients show an association of rs6295 with an increase in raphe 5-HT1A binding potential. A significant association was observed in unmedicated or antidepressant-naive depressed patients . In this cohort, the rs6295 risk allele and genotype also associated with depression. In a replication study, the level of 5-HT1A receptor binding potential correlated with the genetic load, increasing from CC-CG-GG , which also correlated with reduced response to antidepressant treatment. In bipolar depression, the rs6295 genotype also tended to associate with increased raphe 5-HT1A binding . A similar trend of increased 5-HT1A autoreceptor levels was seen using a different 5-HT1A ligand in two female depression patients with the GG genotype . By contrast, in normal subjects, there was a trend for an association of increased 5-HT1A autoreceptor binding potential associated with the GG genotype, but this was not statistically significant . The finding of a more robust increase in 5-HT1A autoreceptor levels with the GG genotype in depressed compared with normal subjects suggests that depressed subjects may not compensate efficiently for the dysregulation conferred by the G(-1019) allele.
Increase in 5-HT1A autoreceptors due to the rs6295 genotype may be augmented by a reduction in synaptic 5-HT release in depression and be reversed by SSRI antidepressants that increase synaptic 5-HT levels. Consistent with this, 5-HT1A autoreceptor levels negatively correlate with levels of the plasmalemmal 5-HT transporter (SERT) in PET studies [137,138], and in post-mortem studies [108,139]. Interestingly, increased 5-HT1A autoreceptor binding is associated with reduced response to antidepressants [102,140], which could reflect greater autoreceptor-mediated inhibition of 5-HT. Treatment of anxiety disorder patients with antidepressants appears to normalize the imbalance between increased 5-HT1A autoreceptor levels and decreased 5-HT1A heteroreceptors . In addition, the level of 5-HT1A autoreceptors is altered by additional factors. For example, the level of 5-HT1A autoreceptor binding potential varies with the oestrous cycle in females , which may account for the increased predisposition of females to depression. Despite these variables and the small numbers of patients that can be studied by PET imaging, these data provide important evidence that the rs6295 polymorphism is functional in humans and leads to alterations in 5-HT1A receptor levels in depression.
Since the initial report of an association of rs6295 with major depression and completed suicide , several studies have replicated these results . A meta-analysis confirmed the association of the G-allele of rs6295 with depression, and found an especially strong association in Asian depression . This could be due to the much lower frequency of the G-allele in Asian populations (10–20%) compared with 40–50% in Caucasian subjects. Thus, a twofold enrichment of the G-allele with depression may be observed in Asians, but a much smaller effect would be present in Caucasians. For example, in a study of a Caucasian Utah cohort with over 300 depressed and 300 control subjects, the G-allele was significantly enriched in depression by only 1.1-fold; the G/G genotype was 1.36-fold enriched . Since these studies, several new association studies with the G-allele of rs6295 have been published for depression [101,146–150], negative emotionality , anxiety [150,152], eating disorder , bipolar depression [104,147], alcohol withdrawal symptoms  and suicide . One study suggests that the G-allele may be most strongly associated with depression with co-morbid anxiety , consistent with the importance of dysregulated Htr1a expression in both disorders. In support of this, the G-allele was associated with reduced amygdala activation in normal subjects . Interestingly, in panic disorder and depressed patients the G-allele associated with increased amygdala activation but reduced right prefrontal cortex activation [157,158], suggesting altered fear circuitry . In addition, recent findings have associated the G(-1019) allele with reductions in cognitive functioning in mismatch, attentional and error monitoring paradigms [159–162]. Importantly, several studies of response to chronic SSRI treatment have found an association with reduced response of rs6295 alone or with other Htr1a polymorphisms [61,143,163–167]. Interestingly, the G-allele is associated with a reduced effect on negative symptoms of atypical antipsychotics that have partial agonist activity at 5-HT1A receptors [168,169]. Thus, the G-allele appears to both confer risk for affective disorders and resistance to antidepressant and antipsychotic treatments that target the 5-HT system.
Not all studies have identified the association of rs6295 with depression or psychological symptoms [170–172]. In these cases, the allele frequency was close to 50 per cent; hence, the expected effect size would be very small as argued already. In addition, stronger associations may be expected by use of ethnically homogenous populations , or examination of robust phenotypes, such as current depression or completed suicide rather than personality traits or suicidal thoughts, as done in the above-mentioned studies. A stronger association of rs6295 with current depression compared with depression traits is consistent with the idea that normal subjects may be able to compensate for 5-HT1A dysregulation in the presence of the G(-1019) allele, as suggested by PET imaging studies (see above). Most importantly, investigation of the association of rs6295 with a specific depression subtype (e.g. depression with co-morbid anxiety ) or specific endophenotypes (e.g. limbic activation, amygdala volume), appears to provide stronger associations in very small depression cohorts [124,157,173]. However, these studies need independent replication. The challenge remains to uncover reliable biomarkers and endophenotypes to distinguish different forms of depression and anxiety. By understanding the actions of specific functional polymorphisms, such as rs6295, it may be possible to sub-categorize different types of depression and rationally design optimal treatment strategies.
Based on studies of the 5-HT transporter long polymorphic repeat (5-HTTLPR), a well-studied promotor polymorphism , the role of early or late life stress in increasing vulnerability to depression or anxiety of the rs6295 polymorphism has also been examined. Unlike the 5-HTTLPR, early life stress did not appear to interact with the Htr1a genotype. The homozygous G(-1019) genotype was associated with panic disorder , but there was no interaction with early life stress. Similarly, no environment effect was seen in children with attention-deficit hyperactivity disorder (ADHD) for the association of the G-allele on emotional or anxiety behaviour . Rather, recent stress may interact more strongly with rs6295 than early life stress in predisposing to depression . Similarly, recent stress events, but not early life events, interacted with the Htr1a G-allele in susceptibility to complete suicide . Similarly, bipolar depressed patients were more likely to be hospitalized after recent stress if they had the G/G Htr1a genotype . In animal models, early life stress leads to region-specific alterations in 5-HT1A receptor levels [177,178] and appears to interact with late life stress to induce deficits in 5-HT1A receptor signalling . Thus, stress-induced dysregulation of 5-HT1A receptor expression may be exacerbated by the presence of the G-allele, leading to increased predisposition to mental illness. Interestingly, the G-allele is associated with a blunted cortisol response to acute stress  and increased stress susceptibility , further suggesting a role for altered regulation of the 5-HT1A autoreceptor in impaired stress response in depressed patients . In agreement with this, mice with an increase in 5-HT1A autoreceptors display impaired stress responses . However, the specific interaction between 5-HT1A genotype and stress on 5-HT1A receptor expression and behavioural outcomes remains to be tested.
Genome-wide association studies have failed to confirm association with candidate genes , in part, because not all candidate gene polymorphisms were examined. However, specific genotype analysis for rs6295 identified an association of the G-allele with more severe depression symptoms and reduced response to citalopram in a subgroup of the STAR*D sample . In the larger sample, rs6295 was not examined, but other 5-HT1A polymorphisms were associated with antidepressant response. Interestingly, preliminary studies suggest that the C-allele may be associated with risk of illnes for premenstrual dysphoria  or ADHD . In a separate ADHD cohort, the G-allele was associated with decreased anxiety-fear disorders . These findings need replication, but may suggest that hyperactivity of the 5-HT system due to fewer 5-HT1A autoreceptors could predispose to certain disorders such as ADHD.
The results from studies in animal models and in human depression and anxiety suggest that altered 5-HT1A receptor expression leads to impaired serotonergic function and predisposes to depression and anxiety disorders (figure 1). The G-allele of rs6295 5-HT1A promoter polymorphism or loss of Deaf1 function is associated with 5-HT1A autoreceptor upregulation in vivo [85,101], and inhibition of 5-HT neuronal firing frequency to reduce 5-HT release . In addition, the C(-1019)G polymorphism reduces 5-HT1A heteroreceptor expression in a cell-specific manner , with loss of Deaf1 reducing 5-HT1A receptor levels in prefrontal cortex . Other Htr1a polymorphisms in linkage disequilibrium with rs6295 have yet to be functionally characterized and may augment pre- or post-synaptic functions of the C(-1019)G change. Finally, stressful life environment, especially recent stress appears to enhance the susceptibility to depression or suicide that is conferred by the G(-1019) allele. Glucocorticoid-mediated downregulation of hippocampal 5-HT1A heteroreceptor expression could synergize with genotype-driven reductions. Presynaptically, glucocorticoid-induced repression may be particularly important in anxiety, whereas in depression, a blunted cortisol response and lack of stress sensitivity could reduce the effect of cortisol. In anxiety, 5-HT1A autoreceptor expression may be unaffected or reduced due to glucocorticoid-induced repression, while post-synaptic 5-HT1A heteroreceptors would be strongly reduced by both cortisol and rs6295 genotype. On the other hand, in depression, a G-allele-driven increase in 5-HT1A autoreceptor expression would mediate a reduction in 5-HT neuronal activity that predisposes to a depression phenotype [19,20].
Based on the different and sometimes opposing roles of pre- and post-synaptic 5-HT1A receptors in 5-HT regulation and behaviour, we propose that selective pharmacological manipulation of 5-HT1A autoreceptors or heteroceptors might provide a way to improve the treatment of depression and anxiety. Potential approaches to selectively target the 5-HT1A autoreceptor could include targeting its greater autoreceptor reserve , Gi3-selective signalling [187,188], or desensitization with biased ligands ; targeting its differentially regulation by transcription factors, such as Deaf1 or Freud1 ; or by enhancing the use of siRNA-based ligands to downregulate its expression . Recently, intranasal administration of a chemical conjugate of an SSRI to 5-HT1A siRNA was shown to selectively reduce 5-HT1A autoreceptor expression and exert a rapid antidepressant effect, suggesting a novel clinical approach for antidepressant treatment . A combination of selective 5-HT1A autoreceptor inactivation and SSRI treatment should lead to more effective and rapidly acting antidepressant treatment strategies.
P.R.A. was supported by operating funds from the Canadian Institutes of Health Research and equipment funding from the Heart and Stroke Centre for Stroke Recovery.